Abstract:The aim of present research work was to prepare, optimized, and evaluate the multi-dose nasal spray solution for delivery of vilazodone hydrochloride to the brain by the intranasal route in order to overcome the drawback associated with the oral route for the treatment of depression. Depression is a mental disorder associated with abnormalities in neuronal transport in the brain primarily serotonin, norepinephrine, and dopamine that adversely affects a person's lifestyle, sleep pattern, work, eating habits, and general health. Vilazodone hydrochloride acts by enhancing the serotonergic activity in the brain by inhibiting serotonin (5-HT) reuptake. The excipients used to formulate vilazodone hydrochloride multi-dose nasal spray solution were sulphobutylether-β-cyclodextrin sodium (solubilizer), sodium carboxymethylcellulose (viscosity builder), tween 80 (surface tension modifier), glycerol (humectant), benzalkonium chloride (preservative), and purified water (vehicle). The simple conventional mixing technique was used for the preparation of the multi-dose nasal spray solution. The solution was prepared in two parts, in the first part sulphobutylether-β-cyclodextrin sodium and drug substance dissolved in purified water under stirring followed by the addition of glycerol and benzalkonium chloride solution. In the second part, tween 80 dissolved in warm water followed by the addition of sodium carboxymethylcellulose under stirring, finally both parts mixed and the required volume was adjusted with purified water. The central composite design was used for the optimization of the formulation. The solution was evaluated for physicochemical properties, selective toxicity, and experimental kinetics. The prepared vilazodone hydrochloride multi-dose nasal spray solution was shown viscosity (40.5 ± 1.65 mPa.s), droplet size distribution (span) (1.88 ± 0.55 µm), spray area (288 ± 1.25 mm2), ovality (1.10 ± 1.35), dripping speed (0.25 cm /30 sec), visual appearance (clear free from particulate matter), pH (6.35 ± 0.10), shot weight (100.6 ± 0.32 mg), density (1.03 ± 0.20 g/ml), % drug content (101.8 ± 0.15 %), displacement value for in-vitro mucoadhesion (3.47 ± 0.25 cm), average flux (Jss) for permeability (241.06 ± 1.45 μg/cm2/hrs), permeability coefficient (48.21 ±1.46 cm/hrs), enhancement ratio (1.73), local toxicity study shows no epithelium cell damage, isotonicity (386.58 mOsmol / kg). Plasma Cmax (24.56 ±3.98 ng/ml), Tmax (1.0 hrs), and AUC 0-12 (82.68 ±10.22 ng.h/ml). Brian tissue Cmax (22.95 ±4.22), Tmax (1.0 hrs) and AUC 0-12 (77.82 ±6.25 ng.h/ml). Nasal bioavailability (251.74 ±45.12% ) and, drug targeting index 1.54 The present research work results showed that the prepared multi-dose nasal spray solution of vilazodone hydrochloride was suitable for the delivery of the drug to the brain by the intranasal route and might be beneficial to overcome drawbacks associated with the oral route of administration for the treatment of depression.

Intranasal co-delivery of berberine and evodiamine by self-assembled thermosensitive in-situ hydrogels for improving depressive disorder

Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity

Alginate nanogels-based thermosensitive hydrogel to improve antidepressant-like effects of albiflorin via intranasal delivery

Thermosensitive hydrogel designed for improving the antidepressant activities of genipin via intranasal delivery

Design, characterization of Resveratrol-Thermosensitive Hydrogel System (Res-THS) and evaluation of its anti-depressant effect via intranasal administration

A novel Thermo-responsive hydrogel system (THS) loaded with the active ingredient of Gardenia jasminoides J. Ellis exhibits anti-depressant effects in vivo via intranasal administration

Anti-depressant effect of curcumin-loaded guanidine-chitosan thermo-sensitive hydrogel by nasal delivery

Intranasal bilosomes in thermosensitive hydrogel: advancing desvenlafaxine succinate delivery for depression management

Stimuli-responsive nanoparticles delivered by a nasal-brain pathway alleviate depression-like behavior through extensively scavenging ROS

Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients

Intranasal Delivery of Near‐infrared and Magnetic Dual‐response Nanospheres to Rapidly Produce Antidepressant‐like and Cognitive Enhancement Effects

Enhanced antidepressant effects of BDNF-quercetin alginate nanogels for depression therapy

Brain Targeting of Venlafaxine via Intranasal Transbilosomes Thermogel for Improved Management of Depressive Disorder

Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: II. Antidepressant Effect in an Experimental Animal Model

Novel Engineered Microgels with Amphipathic Network Structures for Simultaneous Tumor and Inflammation Depression

Borneol-modified PEGylated Graphene Oxide As a Nanocarrier for Brain-Targeted Delivery of Ginsenoside Rg1 Against Depression.

Microneedle-mediated nose-to-brain drug delivery for improved Alzheimer's disease treatment

Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder

Chitosan Nanoparticles Embedded in In Situ Gel for Nasal Delivery of Imipramine Hydrochloride: Short-Term Stage Development and Controlled Release Evaluation

Transferrin-modified Carboxymethyl Chitosan-Chitosan Nanoparticles As an Efficient Delivery Carrier for Targeted Therapy of Depression

Vilazodone Hydrochloride Multi-Dose Nasal Spray Solution for the Treatment of Depression: Design, Optimization, and Evaluation